Cereno Scientific focuses on developing innovative treatments for diseases with high unmet medical needs.

Cereno Scientific

Cereno Scientific focuses on developing innovative treatments to enhance and extend the lives of patients with high unmet medical needs.

Cereno Scientific | 1,883 followers on LinkedIn. Developing innovative treatments for patients affected by common and rare cardiovascular diseases. | Cereno Scientific is a clinical stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH) and thrombotic indications. CS1 is an HDAC (Histone DeACetylase) inhibitor that acts as an epigenetic modulator with anti-thrombotic, anti-inflammatory, anti-fibrotic and pressure-relieving properties, all relevant for PAH.

Michael Holinstat

CEO @ Cereno Scientific AB | Entrepreneur, Board Professional

Sten R. Sörensen

CFO at Cereno Scientific

Eva Jagenheim

Senior Advisor

Jan-Peter Idström

The abstract on CS585, co-authored by Dr. Michael Holinstat , to be presented at the AHA Scientific Sessions 2024 this weekend is now available on the congress website. The abstract titled “Sustained Anti-Thrombotic Efficacy Of CS585, A Novel Prostacyclin Receptor Agonist, Demonstrates Therapeutic Potential”, was authored by L. Stanger, M Flores, P Yalavarthi and M. Holinstat, at University of Michigan, Ann Arbor, USA; and B. Dahlöf, Cereno Scientific, Gothenburg, Sweden. The abstract will be presented by Livia Stanger , Graduate student at the Holinstat Lab at University of Michigan, led by Dr. Michael Holinstat, Professor in the Department of Pharmacology, the Department of Internal Medicine (Division of Cardiovascular Medicine), and the Department of Vascular Surgery at the University of Michigan. Dr. Holinstat leads Cereno’s development programs at the University of Michigan and is Director of Translational Research at Cereno. Dr. Michael Holinstat has been invited to introduce the session where the CS585 abstract is presented, with a presentation titled “New Mechanisms For Antiplatelet Therapies”. The abstract will be presented on Saturday, 16 November, 15:15–16:30 CST, as part of the session “Translational Discovery in Thrombosis and Anti-thrombotic Therapeutics”. Read the full abstract here: https://lnkd.in/d36nJHgm

Cereno Scientific secures minimum 250 MSEK loan financing to reach set milestones into 2026 The Financing Agreement includes a cash loan in two tranches totaling 175 MSEK as well as the issue of convertible loans of 75 MSEK with Fenja Capital II A/S and the US-based investor Arena Investors, LP. The Financing Agreement secures the financial runway for Cereno Scientific to reach its set milestones into 2026. Read the full press release here: https://lnkd.in/dcaSsCeU

Wrapping up the final day at BIO Europe 2024 in Stockholm! Our CEO Sten R. Sörensen , CMO & Head of R&D Dr. Rahul Agrawal , and Director of Business Development Julia Fransson have had an inspiring and productive experience filled with meaningful discussions with potential partners, investors, and industry peers.

New BioStock interview with CEO Sten R. Sörensen Cereno Scientific’s CEO sat down with BioStock to talk about the Company’s current projects, our objectives at BIO Europe, and the future ahead. See the full interview here: https://lnkd.in/dceT2XpD "

Edison Investment Research increases valuation of Cereno Scientific to 4.05 BSEK or SEK 14.3 SEK/share after IPF selected as initial target indication for CS014. Read the full research here: https://lnkd.in/ec2r4nWy

Cereno Scientific’s Capital Markets Day 2024 was a success! We had over 50 shareholders and analysts joining us at Posthuset in Stockholm, several hundred listening in live. Tune in to hear CEO Sten R. Sörensen talk about Cereno Scientific's strategic focus and future outlook; CMO and Head of R&D Rahul Dr. Agrawal present the Phase II trial results of CS1 in rare disease PAH as well as the next steps for CS1; Dr. Raymond L. Benza give an introduction to PAH, a debilitating rare disease; Jason L. Guichard, gives an investigator and patient perspective on the Phase II trial; CEO of Fluidda, Jan De Backer talks about the Fluidda technology and the collaboration with Cereno; CSO Dr. Björn Dahlöf and Nick Oakes introduces IPF as the new target indication for novel HDACi CS014; and Professor Michael Holinstat gives an update on CS585 being evaluated in rare diseases. Subtitles will be added in a few days.

Tune in for Cereno Scientific's Capital Markets Day today, Thursday October 17, at 13:30 CET! See here for an updated agenda for the Capital Markets Day: https://lnkd.in/dF2BSt7W Register here to participate online: https://lnkd.in/djQdTmsY

Cereno Scientific pivots to rare disease Idiopathic Pulmonary Fibrosis (IPF) as the initial target indication for novel HDAC inhibitor CS014 – strengthens Company focus on rare diseases The Company has selected rare disease Idiopathic Pulmonary Fibrosis (IPF) as the initial target indication for novel HDACi CS014. This decision follows recent preclinical results showing significant reductions in pulmonary artery occlusion and fibrosis. With this move, Cereno strengthens its focus on rare diseases, reinforcing its commitment to addressing the significant needs of patients affected by these conditions. Read the full press release: https://lnkd.in/d2VkXgNh

Join me at BIO-Europe, November 4–6, 2024, in Stockholm, Sweden, where the event marks 30 years of facilitating partnerships.

🔔 Reminder: Cereno Scientific’s Capital Markets Day – Join Us Online! 🔔 We are just days away from our highly anticipated Capital Markets Day. While in-person attendance is fully booked, there’s still an opportunity to participate virtually. 💡 Don’t miss this chance to gain valuable insights into our latest developments and future growth strategy. Our executive management team as well as key external speakers will present, a detailed agenda will be provided ahead of time. 📅 Date: October 17 ⏰ Time: 13:30–16:30 CET 💻 Venue: Online 🔗 Register here: https://lnkd.in/djQdTmsY We look forward to sharing our vision and the exciting milestones ahead with you. If you don’t have the opportunity to join us in real-time, a video will be posted after the event at Cereno’s website, Youtube and LinkedIn.

Metric
Company Name	Cereno Scientific
Symbol
MSH ID	COM:CERENOSCIENTIFIC
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biotechnology
Country	SE
Stage
Employee Count
Website	cerenoscientific.com
LinkedIn	cereno-scientific-ab
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

CERE

COM:CERENOSCIENTIFIC

Cereno Scientific

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue